Other news to note for June 16, 2020

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Acepodia, Adagene, Adaptive, Alphamab Oncology, Astrazeneca, Atum, Biocryst, Bold, Canbridge, Catalent, Celltrion, Chelation, Chrysalis, Debiopharm, Dr. Reddy's, Dyadic, Egle, Emergent, Fujifilm, Gilead, Grifols, Innovation, Intas, Izana, Johnson & Johnson, Kalytera, Leading, Lyvgen, Merck, Microsoft, Mitsubishi Tanabe, Mymetics, Naari, Oblique, Oncolys, Orgenesis, Panacea, Pharmabcine, Pharmamar, Phylex, Qualigen, Refana, Regeneron, Sanofi, Serimmune, Takeda, Thermo Fisher Scientific, Thermogenesis, Transposon, TTY Biopharm, Twist, Vault.

Financings for June 16, 2020

Biopharmas in Asia-Pacific raising money in public or private financings, including: Albireo, Appili, JW Therapeutics (Shanghai) Co., Immvira, Shattuck Labs, Takeda.

Appointments and advancements for June 16, 2020

New hires and promotions in the biopharma industry in Asia-Pacific, including: Canbridge Pharmaceuticals.

Regulatory front for June 16, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: Department of Defense, FDA, Minister of Health, National Center for Advancing Translational Sciences, NIH.

Clinical data for June 9-15, 2020

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Atyr, Can-Fite, Eli Lilly, Humanigen, Immunic, Kyowa Kirin, Moderna, Neurorx, Oncoimmune, Opko Health, Opthea, Orpheris, Otsuka, Pluristem, Regeneron, Relief, Sinovac, Solasia, Tychan.

Regulatory actions for June 9-15, 2020

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Biophytis, Diffusion, Fulcrum, Genequantum, Immune, Immunic, Immuron, Redhill, Revive.

No Comments